TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The validations confirm the completion of the applications and commence the scientific review process
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated
